Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 4/20 | 0.42 |
| ▸ | TGM2 | P21980 | 1/20 | 0.41 |
| ▸ | PYCR1 | P32322 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9680305 | 0.93 | ALDH1A1 (0.44) | CYP2A6TAAR1HTR2AMEN1KMT2A | |
| SCHEMBL6364651 | 0.85 | MAOB (0.40) | MEN1KMT2ALMNAMAOB | |
| Phenylacetaldehyde SCHEMBL10522053 | 0.80 | ALDH1A1 (0.60) | TAAR1MEN1KMT2ALMNAMAOB | |
| SCHEMBL27943267 | 0.79 | IDO1 (0.40) | CYP2A6TAAR1HTR2AMEN1KMT2A | |
| Bromobenzene SCHEMBL27691130 | 0.79 | ALDH1A1 (0.42) | MAOBEPHX1 | |
| SCHEMBL4628332 | 0.78 | TRPA1 (0.46) | MAOB | |
| SCHEMBL13673478 | 0.78 | CYP2A6 (0.44) | CYP2A6TAAR1HTR2AMEN1KMT2A | |
| SCHEMBL6017301 | 0.78 | CYP2A6 (0.44) | CYP2A6TAAR1HTR2AMEN1KMT2A | |
| SCHEMBL98013 | 0.77 | TAAR1 (0.50) | CYP2A6TAAR1HTR2AIDO1TGM2 | |
| SCHEMBL525153 | 0.77 | CYP2A6 (0.46) | CYP2A6MEN1KMT2ALMNAMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 445 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119684202-A | 1, 4-Dihydropyridine derivative, and preparation method and application thereof | 中国石油大学(华东) | 2025-03-25 | — | — | CN | claimed |
| CN-117417676-A | Coating and preparation method thereof, coating and preparation method of biological material containing coating | 深圳库珀医疗股份有限公司 | 2024-01-19 | — | — | CN | claimed |
| WO-2023131951-A1 | NOVEL DERIVATIVES OF NON-CODED AMINO ACIDS AND THEIR USE AS HERBICIDES | FORTEPHEST LTD. (IL) | 2023-07-13 | — | — | WO | claimed |
| WO-2022130403-A1 | NEW QUATERNARY AMMONIUM SALTS FOR TRIFLUOROMETHYLATION AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2022-06-23 | — | — | WO | claimed |
| CN-107686475-B | Synthesis method of 2,3, 5-trisubstituted thiophene and derivatives thereof | 湘潭大学 | 2020-09-25 | — | — | CN | claimed |
| WO-2015102020-A1 | NOVEL N-HETEROCYCLIC CARBENE COMPOUNDS, THEIR PREPARATION AND USE | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2015-07-09 | — | — | WO | claimed |
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | UNIV YALE (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4034094-B1 | PHOSPHODIESTERASE INHIBITORS AND USE | ZENSHINE PHARMACEUTICALS NANJING GROUP CO LTD (CN) | 2026-04-15 | — | — | EP | disclosed |
| EP-4716685-A1 | IMIDAZO[4,5-C]PYRIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2026-04-01 | — | — | EP | disclosed |
| US-20260070906-A1 | IMIDAZO[4,5-C]PYRIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2026-03-12 | — | — | US | disclosed |
| US-12492188-B2 | 1H-benzo[D]imidazole derivatives as TLR9 inhibitors for the treatment of fibrosis | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-12-09 | — | — | US | disclosed |
| US-12479849-B2 | EGFR inhibitors for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2025-11-25 | — | — | US | disclosed |
| US-12377083-B2 | Lysophosphatidic acid receptor antagonist and preparation method therefor | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2025-08-05 | — | — | US | disclosed |
| EP-0485069-B1 | Process for producing optically active amines | SUMITOMO CHEMICAL CO (JP) | 1995-02-15 | — | — | EP | disclosed |
| US-5200561-A | PROCESS FOR PRODUCING OPTICALLY ACTIVE AMINES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1993-04-06 | — | — | US | disclosed |
| EP-0485069-A1 | Process for producing optically active amines | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1992-05-13 | — | — | EP | disclosed |
| CN-86105597-A | Make the method for novel pyrazoline compounds | — | 1987-02-25 | — | — | CN | disclosed |
| US-4003965-A | FIRE RETARDANTS, PREEMERGENCE HERBICIDES | MONSANTO COMPANY (US) | 1977-01-18 | — | — | US | disclosed |
| US-3984400-A | 11-Desoxy-16-aryl-ω-tetranorprostaglandins | PFIZER INC. (US) | 1976-10-05 | — | — | US | disclosed |
| US-3962281-A | METHOD OF PREPARING ALDEHYDES | SAGAMI CHEMICAL RESEARCH CENTER (JA) | 1976-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12377083-B2 | Lysophosphatidic acid receptor antagonist and preparation method therefor | LPAR1, LPAR2, LPAR4 | CYP2A6 1217/4885TAAR1 424/4885HTR2A 646/4885 |
| US-12492188-B2 | 1H-benzo[D]imidazole derivatives as TLR9 inhibitors for the treatment of fibrosis | TLR9, TLR1, TLR7 | CYP2A6 4730/4885TAAR1 563/4885HTR2A 4310/4885 |
| US-20260070906-A1 | IMIDAZO[4,5-C]PYRIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | TLR1, TLR6, TLR8 | CYP2A6 1747/4885TAAR1 397/4885HTR2A 783/4885 |
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, VHL, ADRM1 | CYP2A6 4009/4885TAAR1 3680/4885HTR2A 4010/4885 |
| US-12479849-B2 | EGFR inhibitors for the treatment of cancer | EGFR, ERBB2, ERBB3 | CYP2A6 2873/4885TAAR1 1971/4885HTR2A 2462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.